EPISODE · Apr 16, 2026 · 9 MIN
Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines, BristolMyers Squibb, Bain Capital, Travere Therapeutics, Filspari, sparsentan, FSGS,Daiichi Sankyo, Suntory, Oric Pharmaceuticals, rinzimetostat, Foundayo,orforglipron, Eli Lilly, Allogene, CAR-T, peptides, GLP-1, Q1 earnings, Lilly,AstraZeneca, J&J, GSK, Sanofi, BMS
What this episode covers
J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines, BristolMyers Squibb, Bain Capital, Travere Therapeutics, Filspari, sparsentan, FSGS,Daiichi Sankyo, Suntory, Oric Pharmaceuticals, rinzimetostat, Foundayo,orforglipron, Eli Lilly, Allogene, CAR-T, peptides, GLP-1, Q1 earnings, Lilly,AstraZeneca, J&J, GSK, Sanofi, BMS
NOW PLAYING
Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m